title: Treating Diabetes in Patients with Heart Failure: Moving from Risk to Benefit.
abstract: Over the past two decades, therapeutics for diabetes have evolved from drugs with known heart failure risk to classes with potential benefit for patients with heart failure. As many as 25 to 35 % of patients with heart failure carry a diagnosis of type 2 diabetes mellitus. Therefore, newer drug classes including dipeptidyl peptidase 4 (DPP-4) inhibitors, glucagon-like peptide 1 (GIP-1) agonists, and sodium-glucose cotransporter 2 (SGLT-2) inhibitors are being examined for cardiovascular safety as well as their effects on left ventricular function, quality of life, and other measures of disease progression. The purpose of this review is to summarize the existing evidence on these classes of anti-diabetic agents in patients with heart failure.
authors.affiliation: Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
authors.forename: Ersilia M
authors.initials: EM
authors.lastname: DeFilippis
authors.affiliation: Cardiovascular Division, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, 02115, USA. mgivertz@partners.org.|Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA. mgivertz@partners.org.
authors.forename: Michael M
authors.initials: MM
authors.lastname: Givertz
mesh_terms: D001786:Blood Glucose; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use*; D018450:Disease Progression; D052216:Glucagon-Like Peptide 1 / Q000819:agonists*; D006333:Heart Failure / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D011788:Quality of Life; D051297:Sodium-Glucose Transporter 2; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D016277:Ventricular Function, Left / Q000187:drug effects
chemical_list: D001786:Blood Glucose; D054873:Dipeptidyl-Peptidase IV Inhibitors; D007004:Hypoglycemic Agents; C089180:SLC5A2 protein, human; D051297:Sodium-Glucose Transporter 2; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D052216:Glucagon-Like Peptide 1
keywords: Diabetes; Dipeptidyl peptidase 4 inhibitor; Glucagon-like peptide 1 agonist; Heart failure; Insulin resistance; Sodium-glucose cotransporter 2 inhibitor